Gasmi Mehdi 4
4 · Adverum Biotechnologies, Inc. · Filed Jun 18, 2020
Insider Transaction Report
Form 4
Gasmi Mehdi
VP, Pharmaceutical Development
Transactions
- Exercise/Conversion
Common Stock
2020-06-17$4.80/sh+268$1,286→ 274,710 total - Exercise/Conversion
Common Stock
2020-06-18$4.80/sh+11,127$53,410→ 285,569 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-06-17−268→ 117,732 totalExercise: $4.80Exp: 2026-02-11→ Common Stock (268 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-06-18−11,127→ 106,605 totalExercise: $4.80Exp: 2026-02-11→ Common Stock (11,127 underlying) - Sale
Common Stock
2020-06-17$25.01/sh−268$6,703→ 274,442 total - Sale
Common Stock
2020-06-18$25.01/sh−11,127$278,329→ 274,442 total
Footnotes (4)
- [F1]Shares sold pursuant to a 10b5-1 plan.
- [F2]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $25.00 to $25.04. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F3]Price reported is a weighted-average sales price. The shares were sold at prices ranging from $25.00 to $25.05. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- [F4]Fully vested and exercisable.